Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

National Institute for Health and Clinical Excellence (NICE).

National Institute for Health and Clinical Excellence (NICE); 2012 Dec. 45 p. (Technology appraisal guidance; no. 269).

Conclusions of the Review

The manufacturer's search of the published cost-effectiveness literature describing the use of vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation positive malignant melanoma did not identify any relevant cost-effectiveness studies. The ERG is satisfied with the manufacturer's search strategy and is reasonably confident that the manufacturer did not miss any relevant published articles.